Back to News
Market Impact: 0.4
DBV Seeks FDA Approval For VIASKIN Peanut Patch In Young Children
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
DBV Technologies submitted a Biologics License Application to the FDA for its VIASKIN Peanut Patch to treat peanut allergy in children aged 4-7 years. The company also requested Priority Review, which could accelerate the FDA decision timeline and represents a meaningful regulatory catalyst for DBVT.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
DBVT0.75
More News
- US judge approves settlement allowing Paramount to acquire Warner Bros
- Why is Nidec stock plunging today?
- California Gov. Gavin Newsom bans AI 'robo bosses' in landmark state law, reversing his earlier veto
- Google rolls out Gemini 4 Argon, its most advanced AI model
- OpenAI is sued over rogue AI Hugging Face cyberattack
- Trump's latest global tariffs face trade court challenge